Stock comparison
Pharming Group N.V.
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
PHAR
Pharming Group N.V.
Market cap
$889.88M
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | PHAR | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 37D | 72B | RMD |
| Benjamin Graham | 67D | 75B | RMD |
| Philip Fisher | 43D | 75B | RMD |
| Peter Lynch | 25F | 58C | RMD |
| Joel Greenblatt | 44D | 47D | RMD |
| Charlie Munger | 34F | 69B | RMD |
| Terry Smith | 41D | 73B | RMD |
Side-by-side metrics
| Metric | PHAR | RMD |
|---|---|---|
| Market cap | $889.88M | $30.18B |
| P/E (TTM) | 77.6x | 19.6x |
| EV/EBIT | 50.7x | 17.1x |
| ROIC (TTM) | 3.76% | 19.63% |
| Gross margin | 88.12% | 61.69% |
| Net margin | 3.37% | 27.44% |
| Revenue CAGR 5y | 17.35% | 12.64% |
| EPS CAGR 5y | -33.13% | 30.73% |
| Debt / Equity | 0.4x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PHAR leads on
- Gross margin88.12%vs 61.69%+30%
- Revenue CAGR 5y17.35%vs 12.64%+27%
RMD leads on
- EPS CAGR 5y30.73%vs -33.13%+193%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $889.88M+97%
- Net margin27.44%vs 3.37%+88%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.